Clinical Trials Logo

Filter by:
NCT ID: NCT05580991 Recruiting - Solid Tumor Clinical Trials

Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

Start date: September 9, 2022
Phase: Phase 1
Study type: Interventional

To evaluate CAN1012 when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.

NCT ID: NCT05580952 Recruiting - Clinical trials for Diseases of Aortic Valve

Clinical Trial in China

Start date: October 14, 2022
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to evaluate the effectiveness and safety of the transcatheter aortic valve system in the treatment of patients with severe aortic regurgitation disease who are at high or prohibitive surgical risk.

NCT ID: NCT05580796 Recruiting - Solid Tumor Clinical Trials

KSH01-R02-101 Solid Tumors

Start date: October 11, 2022
Phase: Early Phase 1
Study type: Interventional

1. . safety and tolerance 2. . objective response rate

NCT ID: NCT05580523 Recruiting - Preeclampsia Clinical Trials

Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial

Start date: July 3, 2023
Phase: N/A
Study type: Interventional

This is a prospective, multicenter, randomized controlled, double-blind trial of three treatment arms: (1) aspirin 75 mg/day vs. (2) aspirin 150 mg/day vs. (3) aspirin 75 mg/day with metformin 1.5 g/day from the first trimester to compare the incidence of preterm preeclampsia with delivery at <37 week's gestation between the treatment arms, in order to determine the optimal therapeutic intervention for the prevention of preterm preeclampsia among Chinese women at high-risk of preeclampsia.

NCT ID: NCT05580445 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

Start date: August 11, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the safety, tolerability, pharmacokinetics and antineoplastic activity of CT-707 in combination with toripalimab and gemcitabine in patients with advanced pancreatic cancer

NCT ID: NCT05579925 Recruiting - Atopic Dermatitis Clinical Trials

A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis

Start date: October 7, 2022
Phase: Phase 2
Study type: Interventional

This is a multi-center, single arm, open-label study to evaluate safety and primary efficacy in children patients with moderate-to severe atopic dermatis.

NCT ID: NCT05579366 Recruiting - Ovarian Cancer Clinical Trials

PRO1184 for Advanced Solid Tumors

PRO1184-001
Start date: December 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1184 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

NCT ID: NCT05579353 Recruiting - Colorectal Cancer Clinical Trials

The Roles of Exosomal Circ-LRBA and 451/CRTC2 Signaling Axis in Colorectal Cancer

Start date: January 1, 2023
Phase:
Study type: Observational

Colorectal cancer (CRC) is one of the most common malignant tumors in the world. Most of the patients with colorectal cancer were diagnosed in poor stage. Although 40% to 50% patients of colorectal cancer can be cured by surgery, but most patients have undergent metastasis or recurrence, and eventually death. In recent years, molecular targeted therapy has shown significant efficacy in specific patients. It was necessary to detect the corresponding molecular targets of tumors before selecting appropriate targeted drugs in clinic. The changing state of related gene molecules in colorectal cancer played a key role in drug selection, there were few effective targets so far. At present, metastasis and recurrence still be the most difficult problems in treatment. Therefore, investigators should deeply study the occurrence and development of colorectal cancer at the gene level and look for new biomarkers to predict the prognosis. Furthermore, the study can clarify the exact molecular mechanism of colorectal cancer. These will be important clinical significance for targeted therapy of colorectal cancer.

NCT ID: NCT05579275 Recruiting - Clinical trials for Malignant Solid Tumors

Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors

Start date: February 6, 2023
Phase: Early Phase 1
Study type: Interventional

To evaluate the safety and tolerability of JCXH-212 monotherapy and combined with Toripalimab in patients with malignant solid tumors; to determine the maximum tolerated dose (MTD), and to evaluate the dose-limiting toxicity (DLT) of JCXH-212 monotherapy and combined with Toripalimab.

NCT ID: NCT05579132 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia

Start date: September 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

An effective treatment for adults and children B-ALL represents a significant unmet need. CN201 has demonstrated efficacy in nonclinical models of leukemia .CN201 has a longer half-life, thus long term continuous intravenous infusion is not necessary for clinical use. The present study will be conducted in 2 parts: Phase Ib is a dose finding phase to identify the RP2D. Phase II will allow further evaluation of the safety and efficacy of CN201 at the RP2D.